|
|
Fortrea Holdings Inc (NASDAQ: FTRE) |
|
Price: $17.7800
$-0.67 
-3.631%
|
| Day's High:
| $18.47
| Week Perf:
| 0.51 %
|
| Day's Low: |
$ 17.67 |
30 Day Perf: |
-7.68 % |
| Volume (M): |
977 |
52 Wk High: |
$ 41.02 |
| Volume (M$): |
$ 17,375 |
52 Wk Avg: |
$26.21 |
| Open: |
$18.47 |
52 Wk Low: |
$16.53 |
|
|
| Market Capitalization (Millions $) |
1,600 |
| Shares
Outstanding (Millions) |
90 |
| Employees |
1,800 |
| Revenues (TTM) (Millions $) |
3,539 |
| Net Income (TTM) (Millions $) |
-286 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
18 |
Fortrea Holdings Inc
Fortrea Holdings Inc is a holding company that operates in various industries such as technology, healthcare, and finance. They invest in and manage a diverse portfolio of companies across these sectors. The company focuses on acquiring and developing businesses with strong growth potential and aims to generate long-term value for its shareholders. Fortrea Holdings Inc is known for its strategic approach to investment and its ability to identify promising opportunities in different markets.
Company Address: 8 Moore Drive Durham 27709 NC
Company Phone Number: 295-7600 Stock Exchange / Ticker: NASDAQ FTRE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Fortrea Holdings Inc
Fortrea Holdings Inc. Faces Financial Challenges Despite AI Innovations: A Market Overview
As we approached the financial interval ending June 30, 2024, Fortrea Holdings Inc. (Nasdaq: FTRE), a prominent player in the contract research organization (CRO) sector, faced significant hurdles as reflected in its latest financial results. The company reported a disappointing shortfall per share of $-1.55, a stark decline compared to a modest earnings of $0.32 per share during the same period last year. This significant drop not only showcases a worsening financial situation but also indicates a deterioration from the previous quarter's shortfall of $-1.13.
Revenue on the Decline
In terms of revenue, Fortrea's figures painted a concerning picture. The company experienced a substantial revenue drop of 16.47%, with total earnings falling from $793 million in Q2 2023 to $662.4 million in Q2 2024. Though there was a slight sequential growth of 0.045% from the previous quarter (up from $662.1 million), this marginal increase does little to soften the blow of the overall decline. It?s worth noting that the broader Medical Laboratories sector saw revenue improvements during the same period, highlighting Fortrea?s struggles in contrast to its peers.
|
| Clinical Study
Published Thu, Jun 27 2024 11:00 AM UTC
A Bold Leap Forward: Fortrea Establishes AI Innovation Studio to Transform Clinical Trial Delivery DURHAM, N.C., June 27, 2024 In a groundbreaking move, Fortrea (Nasdaq: FTRE), a prominent global contract research organization (CRO), has unveiled its new artificial intelligence (AI) Innovation Studio. This strategic initiative underscores Fortrea s commitment to leveragi...
|
| Product Service News
Published Tue, Jun 4 2024 11:00 AM UTC
Fortrea, a renowned global contract research organization (CRO), has recently concluded the divestiture of its Enabling Services segment assets, encompassing Endpoint Clinical (Endpoint) and Fortrea Patient Access (FPA) businesses, to Arsenal Capital Partners. This strategic move establishes Fortrea s commitment to building market-leading, technology-rich healthcare and indu...
|
| Product Service News
Published Fri, May 31 2024 5:16 PM UTC
Martin Silver Scholarship for Entrepreneurship: A Prestigious Opportunity for Aspiring InnovatorsThe Martin Silver Scholarship for Entrepreneurship has recently announced its 2024-2025 application cycle, offering a unique opportunity for ambitious undergraduate students seeking to pursue their entrepreneurial dreams. With a generous cash prize of $2,500, this esteemed schol...
|
| Product Service News
Published Thu, May 30 2024 11:00 AM UTC
In an era where inclusivity and diversity are at the forefront of social, economic, and scientific progress, it is imperative that the medical field also reflects the diverse patient populations it serves. Fortrea, a pioneering company in clinical research, has unveiled a groundbreaking solution to enhance diversity and inclusion in this domain. Leveraging real-world data, p...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.21 $ |
| Revenues (TTM) |
39.32 $
|
| Cash Flow (TTM) |
0.01 $ |
| Cash |
1.17 $
|
| Book Value |
16.82 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.21 $
|
| Revenues (TTM) |
39.32 $ |
| Cash Flow (TTM) |
0.01 $ |
| Cash |
1.17 $
|
| Book Value |
16.82 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Change in Scope And Change In Estimated Effort To Complete Contract |
|
 -0.59 % |
of total Revenue |
| North America |
|
47.37 % |
of total Revenue |
| Europe |
|
28.42 % |
of total Revenue |
| Other |
|
24.21 % |
of total Revenue |
|
|
